EE200300213A - SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks - Google Patents

SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks

Info

Publication number
EE200300213A
EE200300213A EEP200300213A EEP200300213A EE200300213A EE 200300213 A EE200300213 A EE 200300213A EE P200300213 A EEP200300213 A EE P200300213A EE P200300213 A EEP200300213 A EE P200300213A EE 200300213 A EE200300213 A EE 200300213A
Authority
EE
Estonia
Prior art keywords
sarp
scleroderma
prevention
treatment
medicament
Prior art date
Application number
EEP200300213A
Other languages
English (en)
Estonian (et)
Inventor
Plater-Zyberk Christine
Power Christine
Colinge Jacques
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200300213A publication Critical patent/EE200300213A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
EEP200300213A 2000-12-06 2001-11-30 SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks EE200300213A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (fr) 2000-12-06 2001-11-30 Utilisation de sarp-1 dans le traitement et/ou la prevention de la sclerodermie

Publications (1)

Publication Number Publication Date
EE200300213A true EE200300213A (et) 2003-08-15

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300213A EE200300213A (et) 2000-12-06 2001-11-30 SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks

Country Status (30)

Country Link
US (2) US7341995B2 (fr)
EP (2) EP1806144A3 (fr)
JP (1) JP2004525869A (fr)
KR (1) KR100804885B1 (fr)
CN (1) CN1323716C (fr)
AT (1) ATE359808T1 (fr)
AU (2) AU2636602A (fr)
BG (1) BG107941A (fr)
BR (1) BR0115983A (fr)
CA (1) CA2428092A1 (fr)
CY (1) CY1107687T1 (fr)
CZ (1) CZ20031855A3 (fr)
DE (1) DE60128009T2 (fr)
DK (1) DK1411970T3 (fr)
EA (1) EA005973B1 (fr)
EE (1) EE200300213A (fr)
ES (1) ES2281463T3 (fr)
HK (1) HK1068106A1 (fr)
HR (1) HRP20030426A2 (fr)
HU (1) HUP0302738A3 (fr)
IL (1) IL156069A0 (fr)
MX (1) MXPA03005027A (fr)
NO (1) NO20032597D0 (fr)
NZ (1) NZ525774A (fr)
PL (1) PL365316A1 (fr)
PT (1) PT1411970E (fr)
SK (1) SK8472003A3 (fr)
UA (1) UA83790C2 (fr)
WO (1) WO2002046225A2 (fr)
YU (1) YU45103A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US7638480B2 (en) 2002-04-10 2009-12-29 Laboratoires Serono Sa Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
CA2597098C (fr) 2005-02-08 2016-08-02 Steven R. Ledbetter Anticorps anti-tgf-beta
US7893018B2 (en) 2005-11-08 2011-02-22 Foundation For Biomedical Research And Innovation Method of treatment for ischemic heart disease
WO2009074637A1 (fr) * 2007-12-13 2009-06-18 Merck Serono S.A. Protéines de fusion sarp-1 et leurs utilisations
US20140148473A1 (en) * 2011-03-11 2014-05-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6433155B1 (en) * 1996-09-24 2002-08-13 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
SK287491B6 (sk) * 1998-10-16 2010-11-08 Biogen Idec Ma Inc. Fúzne proteíny interferónu- beta-1a a ich použitie

Also Published As

Publication number Publication date
CN1553806A (zh) 2004-12-08
MXPA03005027A (es) 2003-09-05
IL156069A0 (en) 2003-12-23
ES2281463T3 (es) 2007-10-01
EA200300639A1 (ru) 2003-12-25
SK8472003A3 (en) 2003-10-07
BG107941A (bg) 2004-01-30
CN1323716C (zh) 2007-07-04
DE60128009T2 (de) 2007-08-23
HK1068106A1 (en) 2005-04-22
EP1806144A3 (fr) 2008-04-23
US7655628B2 (en) 2010-02-02
KR100804885B1 (ko) 2008-02-20
EP1806144A2 (fr) 2007-07-11
KR20030076585A (ko) 2003-09-26
AU2002226366B2 (en) 2007-03-22
HUP0302738A3 (en) 2010-01-28
EP1411970A2 (fr) 2004-04-28
US7341995B2 (en) 2008-03-11
YU45103A (sh) 2006-08-17
PT1411970E (pt) 2007-05-31
EP1411970B1 (fr) 2007-04-18
JP2004525869A (ja) 2004-08-26
ATE359808T1 (de) 2007-05-15
US20080107627A1 (en) 2008-05-08
CA2428092A1 (fr) 2002-06-13
HUP0302738A2 (hu) 2003-11-28
US20050113291A1 (en) 2005-05-26
CY1107687T1 (el) 2012-05-23
EA005973B1 (ru) 2005-08-25
DE60128009D1 (de) 2007-05-31
WO2002046225A3 (fr) 2004-01-08
NO20032597L (no) 2003-06-06
CZ20031855A3 (cs) 2003-09-17
NZ525774A (en) 2006-03-31
WO2002046225A2 (fr) 2002-06-13
PL365316A1 (en) 2004-12-27
NO20032597D0 (no) 2003-06-06
DK1411970T3 (da) 2007-06-04
HRP20030426A2 (en) 2005-04-30
BR0115983A (pt) 2003-12-30
AU2636602A (en) 2002-06-18
UA83790C2 (ru) 2008-08-26

Similar Documents

Publication Publication Date Title
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
MXPA03005731A (es) Articulo absorbente que tiene tratamientos medicinales liberables.
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
SE9904377D0 (sv) Pharmaceutical combinations
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
DE60124516D1 (de) Kombination des lezithins mit ascorbinsäure
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas
WO2002067951A3 (fr) Utilisation de nucleosides 5-substitues et/ou de leurs promedicaments pour traiter des maladies infectieuses sans induire de resistance
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
BR0211522A (pt) Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
ZA200304519B (en) Absorbent article having releasable medicinal treatments.

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner